- Home
- RAMP vs TVTX Comparison
RAMP vs TVTX Comparison
Compare RAMP & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- TVTX
- Stock Information
- Founded
- RAMP 2018
- TVTX 2008
- Country
- RAMP United States
- TVTX United States
- Employees
- RAMP N/A
- TVTX N/A
- Industry
- RAMP EDP Services
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- TVTX Health Care
- Exchange
- RAMP Nasdaq
- TVTX Nasdaq
- Market Cap
- RAMP 1.8B
- TVTX 1.5B
- IPO Year
- RAMP 1987
- TVTX N/A
- Fundamental
- Price
- RAMP $28.38
- TVTX $21.64
- Analyst Decision
- RAMP Buy
- TVTX Strong Buy
- Analyst Count
- RAMP 7
- TVTX 16
- Target Price
- RAMP $39.00
- TVTX $34.53
- AVG Volume (30 Days)
- RAMP 769.2K
- TVTX 1.9M
- Earning Date
- RAMP 11-05-2025
- TVTX 10-30-2025
- Dividend Yield
- RAMP N/A
- TVTX N/A
- EPS Growth
- RAMP 147.00
- TVTX N/A
- EPS
- RAMP 0.22
- TVTX N/A
- Revenue
- RAMP $764,441,000.00
- TVTX $333,865,000.00
- Revenue This Year
- RAMP $10.65
- TVTX $83.26
- Revenue Next Year
- RAMP $8.70
- TVTX $43.19
- P/E Ratio
- RAMP $147.94
- TVTX N/A
- Revenue Growth
- RAMP 12.16
- TVTX 87.94
- 52 Week Low
- RAMP $22.82
- TVTX $9.44
- 52 Week High
- RAMP $36.08
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- RAMP 49.74
- TVTX 78.22
- Support Level
- RAMP $26.89
- TVTX $17.27
- Resistance Level
- RAMP $28.15
- TVTX $19.57
- Average True Range (ATR)
- RAMP 0.67
- TVTX 0.99
- MACD
- RAMP 0.31
- TVTX 0.33
- Stochastic Oscillator
- RAMP 85.66
- TVTX 88.44
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.